Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Why is the Medibank share price trailing NIB over the past year?
3 quality ASX dividend shares that have been sold off
‘Real opportunity’: NIB (ASX:NHF) share price slips following first-half results
Why Ansell, AnteoTech, Dubber, and NIB shares are dropping
Why is the NIB (ASX:NHF) share price sliding 7% today?
How do Medibank (ASX:MPL) dividends compare to NIB?
Here are Scott Phillips’ top 5 ASX shares for 2022. Is it time to buy?
Own NIB (ASX:NHF) shares? Here are the key dates for your investor diary in 2022
|03 Mar 2022||$0.1100||100.00%||Interim||04 Apr 2022|
|02 Sep 2021||$0.1400||100.00%||Final||05 Oct 2021|
|04 Mar 2021||$0.1000||100.00%||Interim||06 Apr 2021|
|03 Sep 2020||$0.0400||100.00%||Final||06 Oct 2020|
|05 Mar 2020||$0.1000||100.00%||Interim||07 Apr 2020|
|02 Sep 2019||$0.1300||100.00%||Final||30 Sep 2019|
|28 Feb 2019||$0.1000||100.00%|
|06 Sep 2018||$0.1100||100.00%||Final||05 Oct 2018|
|01 Mar 2018||$0.0900||100.00%||Interim||03 Apr 2018|
|07 Sep 2017||$0.1050||100.00%||Final||06 Oct 2017|
|02 Mar 2017||$0.0850||100.00%||Interim||03 Apr 2017|
|08 Sep 2016||$0.0900||100.00%||Final||07 Oct 2016|
|02 Mar 2016||$0.0575||100.00%||Interim||01 Apr 2016|
|09 Sep 2015||$0.0600||100.00%||09 Oct 2015|
|04 Mar 2015||$0.0550||100.00%||02 Apr 2015|
|10 Sep 2014||$0.0900||100.00%||Special Cash||03 Oct 2014|
|10 Sep 2014||$0.0575||100.00%||Final||03 Oct 2014|
|05 Sep 2013||$0.0500||100.00%||Final||04 Oct 2013|
|04 Mar 2013||$0.0500||100.00%||Interim||05 Apr 2013|
|05 Mar 2012||$0.0425||100.00%||Interim||05 Apr 2012|
|07 Mar 2011||$0.0400||100.00%||Interim||08 Apr 2011|
|05 Mar 2010||$0.0200||100.00%||Interim||08 Apr 2010|
|14 Sep 2009||$0.0440||100.00%||Final||09 Oct 2009|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
NIB Holdings Limited (ASX:NHF) was originally known as Newcastle Industrial Benefits. The company was established in the Hunter region of New South Wales in 1952 to provide health insurance for workers at the BHP steelworks. Since its humble beginnings, NIB has grown to become a national and international insurer with a notable share of the Australian and New Zealand private health insurance market.
Beyond health insurance, NIB also provides life insurance as well as travel insurance to its customers across Australia and around the world. NIB is now Australia’s third largest provider of travel insurance.
According to the company’s website, NIB provides health insurance to over 1.6 million people across Australia and New Zealand as well as nearly 200,000 international students and overseas workers in Australia.
The health fund was demutualised on 19 July 2007 and, on the same day, became Australia’s first private health fund to list on the ASX. The NIB share price opened its first day of trade at 85 cents and has since gone on to reach as high as $8 in July 2019.
|16 May 2022||$7.15||$-0.13||-1.79%||597,118||$7.28||$7.28||$7.09|
|13 May 2022||$7.28||$0.15||2.10%||1,513,928||$7.15||$7.28||$7.07|
|12 May 2022||$7.13||$-0.11||-1.52%||1,067,574||$7.25||$7.25||$7.08|
|11 May 2022||$7.24||$0.04||0.56%||1,438,657||$7.10||$7.24||$7.06|
|10 May 2022||$7.20||$0.07||0.98%||1,286,742||$7.12||$7.20||$7.08|
|09 May 2022||$7.13||$-0.07||-0.97%||946,441||$7.17||$7.24||$7.10|
|06 May 2022||$7.20||$-0.03||-0.41%||1,254,052||$7.22||$7.29||$7.13|
|05 May 2022||$7.23||$0.11||1.54%||783,280||$7.09||$7.25||$7.04|
|04 May 2022||$7.12||$0.10||1.42%||1,013,947||$7.12||$7.12||$7.02|
|03 May 2022||$7.02||$-0.05||-0.71%||1,133,406||$7.06||$7.18||$7.00|
|02 May 2022||$7.07||$-0.01||-0.14%||940,331||$7.03||$7.12||$7.02|
|29 Apr 2022||$7.08||$0.07||1.00%||611,332||$7.01||$7.08||$6.98|
|28 Apr 2022||$7.01||$0.02||0.29%||672,809||$7.03||$7.10||$6.99|
|27 Apr 2022||$6.99||$0.22||3.25%||2,048,338||$6.78||$7.02||$6.73|
|26 Apr 2022||$6.77||$-0.09||-1.31%||458,435||$6.84||$6.85||$6.77|
|22 Apr 2022||$6.86||$0.03||0.44%||925,332||$6.81||$6.90||$6.77|
|21 Apr 2022||$6.83||$0.17||2.55%||1,528,500||$6.76||$6.86||$6.71|
|20 Apr 2022||$6.66||$0.03||0.45%||856,658||$6.63||$6.74||$6.62|
|07 Mar 2022||Mark Fitzgibbon||Transfer||40||$250,400||
|28 Feb 2022||Anne Loveridge||Buy||11||$74,137||
|26 Nov 2021||Mark Fitzgibbon||Issued||220||$1,515,326||
Issue of securities. 951,637 - Performance Rights
|11 Nov 2021||Mark Fitzgibbon||Sell||47||$340,264||
|22 Sep 2021||Mark Fitzgibbon||Transfer||10||$67,255||
Off-market transfer. Estimated Value
|14 Sep 2021||Mark Fitzgibbon||Sell||30||$199,599||
|14 Sep 2021||Mark Fitzgibbon||Transfer||4||$31,064||
Off-market transfer. Estimated Value
|09 Sep 2021||Mark Fitzgibbon||Sell||30||$200,845||
|09 Sep 2021||Mark Fitzgibbon||Transfer||10||$66,111||
Off-market transfer. Estimated Value
|08 Sep 2021||Mark Fitzgibbon||Sell||25||$168,301||
|08 Sep 2021||Mark Fitzgibbon||Transfer||20||$134,428||
Off-market transfer. Estimated Value
|01 Sep 2021||Mark Fitzgibbon||Buy||142||$968,658||
Conversion of securities.
|01 Sep 2021||Mark Fitzgibbon||Issued||82||$559,194||
Issue of securities.
|01 Sep 2021||Mark Fitzgibbon||Expiry||79||$538,521||
As advised by the company. 731,386 - Performance Rights
|01 Sep 2021||Mark Fitzgibbon||Exercise||142||$968,658||
Conversion of securities. 810,814 - Performance Rights
|30 Aug 2021||Mark Fitzgibbon||Sell||30||$201,000||
|30 Aug 2021||Peter Harmer||Buy||11||$74,998||
|31 May 2021||Steven (Steve) Crane||Sell||47||$293,027||
|27 May 2021||Steven (Steve) Crane||Sell||102||$633,200||
|26 May 2021||David Gordon||Buy||30||$184,795||
|Mr David L Gordon||Non-Executive DirectorNon-Executive Chairman||May 2020||
Mr Gordon has over 20 years' experience as a director of both public and private companies and has experience in the corporate advisory and financial services sector. He is currently Chair of Accent Group Limited and Founding Principal of Lexicon Partners. He was previously a Director and Chair of Ten Network Holdings and held senior roles at Herbert Smith Freehills and boutique investment bank, Wentworth Associates.
|Ms Anne Joan Loveridge||Non-Executive Director||Feb 2017||
Ms Loveridge has over 35 years of experience in banking, wealth management, private equity and property. She has knowledge of financial and regulatory reporting, risk management controls and compliance frameworks. She also has experience as a Committee Chairperson. Formally trained as a Chartered Accountant, Anne has a of experience in financial reporting, auditing, risk, ethics and regulatory affairs following her 31 years with PwC Australia, where she retired as Partner and Deputy Chair in 2015. Through senior leadership roles in the firm, Anne also has experience and a focus on leadership, performance and culture. She was specifically involved in the creation of targets, mentoring and development programs for senior executives, as well as evaluating organisational training programs to identify areas of bias. Anne Loveridge is entitled to receive a retirement benefit from PwC as part of her retirement plan. The amount of the payment was determined at the time of retirement, based on role and tenure with the firm. The benefit is not impacted by the revenue, profits or earnings of PwC. Anne has declared her previous relationship with PwC to the nib Board and the Board is satisfied that it does not affect her independence as Non-Executive Director and does not constitute a conflict of interest. The nib Board has in place mechanisms to manage conflicts of interest where they arise. Anne is a Non-Executive Director of Platinum Asset Management and a Non-Executive Director of National Australia Bank Limited. She is a member of the Risk, Reputation and Investment committee.
|Mr Donal Paul O'Dwyer||Non-Executive Director||Mar 2016||
Mr O'Dwyer is also a Director of nib health funds limited. Industry experience Donal has a knowledge of the health industry globally, after more than 35 years in senior executive and Non-Executive Director roles within the healthcare products and medical device sectors. He went on to gain experience in business, science, engineering, manufacturing and management. During his tenure with Baxter Healthcare, he rose through the ranks from plant manager to President of the Cardiovascular Group Europe, gaining a understanding of the inner workings of business strategy and fiscal management, from the floor of the factory through to the boardroom. He then worked for Cordis (the cardiovascular device franchise of Johnson & Johnson) - initially as European President and later, when he located to the US, he served as Worldwide President. In his role as member of the nib Risk and Reputation Committee, Donal has a interest in environmental, social and governance factors and how these performance indicators can help promote long-term financial success. Donal is a Non-Executive Director of Cochlear Ltd, Mesoblast Ltd (Chair of the Nomination and Remuneration Committee) and Fisher & Paykel Healthcare Corporation Ltd. He was director of Chair of CardieX Limited (formerly AtCor Medical Holdings Limited). He is Chair of the Investment committee and a member of the Risk and Reputation and People committee.
|Mark Fitzgibbon||Chief Executive OfficerManaging Director||May 2007||
Mr Fitzgibbon has held executive positions at a number of large Australian organisations, including local government councils and peak bodies. Mark has previously served as CEO of both the national and NSW peak industry bodies for licensed clubs, as well as holding several General Manager positions in local government. He is currently a Director of Private Healthcare Australia.
|Ms Lee Ausburn||Non-Executive Director||Nov 2013||
Ms Ausburn has more than 30 years of experience in the pharmaceuticals industry. Lee is a pharmacist with experience in retail and hospital pharmacy, as well as in academia. She had a long career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President - Asia for Merck and Co Inc with responsibility for the company's operations across nine countries. She also has marketing experience with customer centric. Operating in a highly regulated industry, Lee also developed regulatory and government relations skills. She also has experience operating joint ventures, including chairing the Far East Operating Board. Lee was previously a member (2010-2015) and President (2015- 2017) of the Pharmacy Foundation at the University of Sydney. In NSW, she was a Board member of NSW Health's Clinical Excellence Commission and the Agency for Clinical Innovation (2010-2014), established to enhance quality and safety in NSW hospitals. Lee is currently a Director of pharmaceutical wholesaling and pharmacy retail business, Australian Pharmaceutical Industries Ltd. She is Chair of the People committee and a member of the Risk and Reputation committee.
|Mr Peter Harmer||Non-Executive Director||Jul 2021||
Mr Harmer has over 40 years' experience in the Australian and international insurance and financial sectors, including over 30 years in a senior executive capacity. He was formerly Chief Executive Officer of Insurance Australia Group (IAG), CGU Insurance, Aon Limited UK, Aon Risk Services Australia Pacific and Aon Re Australia. Mr Harmer was also Chairman of Aon Re Australia and the London Market Reform Group and is currently a Non-Executive Director of the Commonwealth Bank of Australia.
|Ms Jacqueline Chow||Non-Executive Director||Apr 2018||
Ms Chow has more than 20 years of experience working with global blue-chip consumer product multinationals in a range of executive and non-executive positions in general management, strategy, marketing as well as technology and innovation. Her early career concentrated on business analytics, brand equity and marketing. She has global experience driving strategic growth and innovation across customer and consumer brands for the likes of Fonterra, Campbell Arnott's and the Kellogg Company. She was previously Deputy Chair of Global Dairy Platform and a Director of Fisher & Paykel Appliances in New Zealand, Dairy Partners Americas, the Riddet Institute (Massey University NZ) and The Arnott's Foundation. In her role with McKinsey & Company RTS, she advises clients across resources, retail, financial services, telecommunications and consumer sectors on organisational change and high performance culture. She is Non-Executive Director of the Australia-Israel Chamber of Commerce and a senior advisor with McKinsey & Company RTS. She is also a member of Chief Executive Women. She is Chair of the Risk and Reputation committee and a member of the People and Investment committee.
|Mrs Michelle McPherson||Deputy Chief Executive OfficerChief Financial Officer||Sep 2008||
|Ms Roslyn Toms||Group Executive - Legal and Chief Risk OfficerCompany Secretary||Apr 2013||
|Mr Jordan French||Senior Corporate CounselJoint Company Secretary||Aug 2017||
|Edward Close||Chief Executive Australian Residents Health Insurance||
|James Barr||Chief Executive International Visitors||
|Anna Gladman||Chief Executive nib Travel||
|Nick Freeman||Chief Financial Officer||
|Brendan Mills||Chief Information Officer||
|Matt Paterson||Chief Operations Officer||
|Martin Adlington||Chief People Officer||
|Michelle McPherson||Deputy Chief Executive OfficerChief Financial Officer||
|Roslyn Toms||Group Executive - Legal and Chief Risk OfficerCompany Secretary||
|Jordan French||Senior Corporate CounselJoint Company Secretary||
|HSBC Custody Nominees (Australia) Limited||76,781,000||16.77%|
|Citicorp Nominees Pty Limited||33,999,128||7.43%|
|J P Morgan Nominees Australia Pty Limited||33,045,560||7.22%|
|National Nominees Limited||15,798,859||3.45%|
|BNP Paribas Noms Pty Ltd||7,731,251||1.69%|
|Bnp Paribas Nominees Pty Ltd||5,440,256||1.19%|
|Citicorp Nominees Pty Limited (i)||4,381,265||0.96%|
|Mirrabooka Investments Limited||1,350,000||0.29%|
|Mr Mark Anthony Fitzgibbon||1,296,366||0.28%|
|BNP Paribas Nominees Pty Ltd Six Sis Ltd||1,239,620||0.27%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd||1,050,124||0.23%|
|HSBC Custody Nominees (Australia) Limited (i)||1,013,776||0.22%|
|CPU Share Plans Pty Ltd||960,641||0.21%|
|BNP Paribas Nominees Pty Ltd (i)||913,923||0.20%|
|Fitzy (Nsw) Pty Ltd||824,621||0.18%|
|BNP Paribas Noms Pty Ltd (i)||769,996||0.17%|
|AMP Life Limited||732,813||0.16%|
|Mrs Michelle Mcpherson||587,911||0.13%|
|Modane Pty Ltd||459,744||0.10%|